Gadin Biotech

Gadin Biotech is a pre-clinical stage biotechnology company focused on developing transformative small molecule therapies for neurodegenerative diseases. The company's proprietary platform targets G-quadruplex (G4) structures and the G-quadruplex-associated DNA-binding protein (GADIN), which are critical regulators of genomic stability and protein synthesis in the brain. By modulating these pathways, Gadin aims to prevent the toxic protein aggregation and neuronal loss characteristic of Alzheimer's and Parkinson's diseases. Founded as a spin-off from the Hebrew University of Jerusalem, the company leverages the pioneering research of Professor Hermona Soreq. Gadin Biotech is currently advancing its lead candidates through early-stage development to address significant unmet needs in the aging population.